2.1 Objective of the Project
To measure and analyze epidemiological data arising from the Product rollout, to determine whether herd immunity is achieved after reaching a certain percentage of vaccination coverage in Israel.
2.2 Principles of Collaboration.
The Parties agree that the Project is intended to generate and analyze epidemiological and population level vaccine effectiveness data, vitally necessary for public health purposes that may inform vaccine technical recommendations globally. The data generated by the Project is aimed at helping end the global COVID-19 pandemic for the benefit of all patients inside and outline of Israel. The Project will be based on the current medical literature, and guidelines adopted by the respected medical bodies.
To conduct the Project and measure population level impact of the Project, MoH is relying on receipt of Product doses, in accordance with the terms of the Manufacturing and Supply Agreement, as may be amended from time to time, and on the project delivery rate by PFIZER to allow maintaining vaccination rate sufficient to achieving herd immunity and enough data as soon as possible, and should be agreed by the two Parties. Nothing in this agreement shall modify or amend in any way the terms of the Manufacturing and Supply Agreement. In case of a conflict between terms of the Manufacturing and Supply Agreement in regard to the manufacturing and supply of the Product, the terms of the Manufacturing and Supply Agreement will control. [redacted text]
2.3 Collaboration & Governance
During the Term, unless the Parties mutually agree to a different frequency, the Parties shall meet weekly by video conference/teleconference at a mutually convenient time to review and discuss the status of the development and implementation of the Project. Project team members shall be determined by the Parties. Each Party shall be responsible for its own costs associated with any meetings.